Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tiotropium/Salmeterol Inhalation Powder in COPD
Sponsor: Boehringer Ingelheim
Summary
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index (BDI)/Transition Dyspnoea Index (TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations
Official title: A 24-week (+ 24 Week Extension) Placebo-controlled (Only 1st 12-week Period), Double-Blind, Parallel-group, Efficacy and Safety Comparison of Fixed-dose Combination (FDC) Tiotropium/Salmeterol, Tiotropium, Salmeterol and FDC Tiotropium/Salmeterol Plus Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) Patients
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
207
Start Date
2008-04-15
Completion Date
2008-11-21
Last Updated
2026-07-16
Healthy Volunteers
No
Conditions
Interventions
Tiotropium/Salmeterol
Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene (PE) Capsule
Salmeterol
Salmeterol Inhalation Powder, hard PE capsule
Placebo
Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
Tiotropium
Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
Locations (64)
1184.15.01069 Boehringer Ingelheim Investigational Site
Anniston, Alabama, United States
1184.15.01071 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
1184.15.01054 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1184.15.01063 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1184.15.01064 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1184.15.01065 Boehringer Ingelheim Investigational Site
Savannah, Georgia, United States
1184.15.01052 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
1184.15.01055 Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
1184.15.01058 Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
1184.15.01062 Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
1184.15.01072 Boehringer Ingelheim Investigational Site
Summit, New Jersey, United States
1184.15.01053 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
1184.15.01070 Boehringer Ingelheim Investigational Site
New York, New York, United States
1184.15.01057 Boehringer Ingelheim Investigational Site
Elizabeth City, North Carolina, United States
1184.15.01059 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1184.15.01051 Boehringer Ingelheim Investigational Site
Morgantown, West Virginia, United States
1184.15.43052 Boehringer Ingelheim Investigational Site
Gänserndorf, Austria
1184.15.43053 Boehringer Ingelheim Investigational Site
Vienna, Austria
1184.15.02057 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1184.15.02059 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1184.15.02055 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1184.15.02058 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
1184.15.02051 Boehringer Ingelheim Investigational Site
Scarborough Village, Ontario, Canada
1184.15.02053 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1184.15.02060 Boehringer Ingelheim Investigational Site
Longueuil, Quebec, Canada
1184.15.02056 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1184.15.45054 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
1184.15.45052 Boehringer Ingelheim Investigational Site
Kolding, Denmark
1184.15.45051 Boehringer Ingelheim Investigational Site
Odense C, Denmark
1184.15.45053 Boehringer Ingelheim Investigational Site
Silkeborg, Denmark
1184.15.37252 Boehringer Ingelheim Investigational Site
Kohtla-Järve, Estonia
1184.15.37251 Boehringer Ingelheim Investigational Site
Tallinn, Estonia
1184.15.35852 Boehringer Ingelheim Investigational Site
Oulu, Finland
1184.15.35851 Boehringer Ingelheim Investigational Site
Tampere, Finland
1184.15.3350A Boehringer Ingelheim Investigational Site
Marseille, France
1184.15.3351A Boehringer Ingelheim Investigational Site
Nantes, France
1184.15.3352A Boehringer Ingelheim Investigational Site
Paris, France
1184.15.49056 Boehringer Ingelheim Investigational Site
Aschaffenburg, Germany
1184.15.49053 Boehringer Ingelheim Investigational Site
Frankfurt, Germany
1184.15.49057 Boehringer Ingelheim Investigational Site
Gelnhausen, Germany
1184.15.49052 Boehringer Ingelheim Investigational Site
Hanover, Germany
1184.15.49058 Boehringer Ingelheim Investigational Site
Hanover, Germany
1184.15.36055 Boehringer Ingelheim Investigational Site
Deszk, Hungary
1184.15.36053 Boehringer Ingelheim Investigational Site
Érd, Hungary
1184.15.36054 Boehringer Ingelheim Investigational Site
Szarvas, Hungary
1184.15.36052 Boehringer Ingelheim Investigational Site
Szeged, Hungary
1184.15.39051 Boehringer Ingelheim Investigational Site
Florence, Italy
1184.15.37154 Boehringer Ingelheim Investigational Site
Balvi, Latvia
1184.15.37152 Boehringer Ingelheim Investigational Site
Jelgava, Latvia
1184.15.37153 Boehringer Ingelheim Investigational Site
Tukums, Latvia
1184.15.37053 Boehringer Ingelheim Investigational Site
Klaipėda, Lithuania
1184.15.31051 Boehringer Ingelheim Investigational Site
Breda, Netherlands
1184.15.31054 Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
1184.15.31052 Boehringer Ingelheim Investigational Site
Zutphen, Netherlands
1184.15.42153 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1184.15.42154 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
1184.15.27051
Bellville, South Africa
1184.15.27052
Cape Town, South Africa
1184.15.27053
Somerset West, South Africa
1184.15.82051 Boehringer Ingelheim Investigational Site
Jeonju, South Korea
1184.15.82052 Boehringer Ingelheim Investigational Site
Suwon, South Korea
1184.15.82053 Boehringer Ingelheim Investigational Site
Wŏnju, South Korea
1184.15.46053 Boehringer Ingelheim Investigational Site
Boden, Sweden
1184.15.46051 Boehringer Ingelheim Investigational Site
Stockholm, Sweden